iFDA: Social Media, the Internet, and Drug Regulation
This article was originally published in RPM Report
Executive Summary
Promotion and marketing is no longer limited to television, newspapers, magazines and journals. The internet is taking on a bigger role in getting through to consumers and doctors. FDA is focusing on how to regulate the rapidly changing landscape. For drug manufacturers, adding clarity is a good thing.
You may also be interested in...
Go Ahead and Advertise--If You Dare
Congress agrees with the pharmaceutical industry that the right to advertise new drugs is protected by the First Amendment. But pharma companies have a long way to go to prove to their critics that it is the right thing to do.
The Blog of War
Former FDA Associate Commissioner for External Relations Peter Pitts explains the emergence of blogging in the health care world and the value the practice serves for discussing health policy.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.